Dr
Satya
Dash
|
![](/IMG/580/46580/satyadashable.jpg) |
Dr Satya Dash is the COO of Association of
Biotechnology Led
Enterprises (ABLE), the pan Indian apex biotechnology industry body. He
is based out of Bangalore, India |
This is the 9th year that BioSpectrum & ABLE have collaborated to
track the biotechnology industry growth in India. This yearly survey is
eagerly awaited by all the stakeholders interested in the status report
and growth opportunities in this vibrant knowledge-based industry.
It is clear from the revenue statistics that the trend of growth in
this industry has continued and the industry has crossed
![](http://www.biospectrumindia.com/images/content/2010/aug/INR-currency_symbol.jpg)
18,000 crore
or $4 billion in dollar terms, posting a 21 percent growth over
previous year’s revenues of over
![](http://www.biospectrumindia.com/images/content/2010/aug/INR-currency_symbol.jpg)
14,000 crore (approx $3 billion).
However, despite the expectations, the industry has not touched $5
billion yet – perhaps the after effects of the severe recession in 2008
are still being felt globally.
Established Players & New
Entrants
It is interesting to note the overall ranking in this sector. While the
top players have maintained their positions with Biocon, Serum &
Panacea leading the way, Transasia and Ankur Seeds have posted
exponential growth figures to leapfrog to 10th & 11th position
respectively. Continuing the trend of growth in the seed business,
Krishidhan Seeds has also climbed to join the top 20 firms.
Other biotech SMEs that have shown incredible growth over the last year
are Anthem Biosciences, JK Agrigenetics, Metahelix, Bayer Cropscience,
Ecron Acunova and Semler Research. Surprisingly though, many
established players have seen a fall in revenues such as Shantha
Biotech, Jubilant Life Sciences and Suven Life Sciences.
The Southern-Western Leadership
The southern region is slightly ahead of the western region in terms of
total share of revenues, however, the south comfortably leads in the
number of firms (172 vs 137). Bangalore and Hyderabad are leading the
way and the recent announcement of building a cluster and incubator in
Bangalore will help maintain the leadership of this region. The north
cluster follows at the third spot but hopefully new clusters,
especially in the NCR, will help close the gap in the future. What is
revealing is, that despite possessing huge bio-resources and many
leading institutions, the eastern part of India is lagging in terms of
proper biotech enterprises. The states of Bihar, West Bengal, Orissa,
Assam and the North East need a focused strategy to seed biotech
enterprises.
The survey shows that there are now 362 firms in India that are
focussed on some aspects of biotechnology. This is an important
indicator. The vibrancy of a knowledge intensive and highly regulated
industry such as biotech depends on the number of new start-up firms
that are establishing and injecting fresh business ideas, solutions,
and products built on innovation. What do we need to have in policy
terms to say that India can treble the number of innovative biotech
firms in the next five years to cross the one thousand mark? How do we
make the biotech landscape investor friendly and ease the burden of
establishing and operating start-ups? Indeed for the sector to grow
even further several concomitant factors have to be addressed:
Streamlining Regulation: Regulation that enables innovation is the key.
ABLE facilitated, as “Knowledge Partner” a regulatory session at
Bangalore INDIA BIO last month. What became clear from discussions
there as well as from all other fora is, that Industry will like to
have a scientific evidence-based, clear and non-ambiguous, streamlined
and transparent regulatory mechanism where procedural delays are
minimized and technical considerations are dealt with by expert
committees that are not created on an ad-hoc basis.
For India to achieve a leadership position in biotechnology, this is
foremost in all sectors of biotechnology, i.e., biopharma (including
diagnostics & devices), agri-biotech and industrial biotech
including food & nutrition. Indeed, it goes without saying that
investor confidence is directly linked to a clear and streamlined
regulatory landscape.
Early Stage Funding
The unique nature of this sector necessitates very early stage funding
especially at the “pre-prototype” stage, for this is where the risks
are at their highest for both big and small biotech firms alike. While
SBIRIs and BIPPs have injected much-needed early stage funding, India
has to find a mechanism to scale-up these funding mechanisms. The
recent DBT-Wellcome Trust initiative in “R&D for affordable
healthcare” is indeed a step in the right direction. Another important
bottleneck has been the “DSIR certification” criteria for access to
these funding schemes. Perhaps streamlining the DSIR certification
process such that valuable time and energies are not lost for firms
will go a long way.
Access to Technology Resources
Common access to efficiently-run technology platforms for the industry
is crucial as it saves cost and time while it allows firms to conduct
cutting edge development of products.
The Future Ahead
Indian biotechnology industry is showing signs of consistent and mature
growth in the 20 percent range. It has done well despite the global
recession. Indian biotech firms are globalizing and strategically
partnering with other firms – the Pfizer-Biocon and Glenmark-Sanofi
deals are indicators of the kinds of new partnerships to emerge.
It is clear that vaccines, diagnostics and devices along with
biosimilars will be key growth areas in biopharma. The agri-biotech
sector is poised to grow – especially, the seed business in the area of
new hybrids. Regulatory clarity in both biopharma/healthcare &
agribiotech will be crucial for the future. There is a perceptible
dynamism in systems biology (or BioIT) firms that are building
predictive models, both disease and organ models, and enabling drug
discovery research.
The growth potential of BioIT firms in India built on India’s strengths
in IT and biology remains high. The CRO industry has become highly
competitive and many CROs now have to show unique differentiation other
than cost arbitrage. Many CROs have chosen to follow a risk-sharing
model for growth to transition themselves into drug discovery firms.
While this transition might take years it is a positive trend for the
industry.